BioPharma Resources

Drug Trial Radar · NCT07664735

A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Jun 2030

Study completion Sep 2030

Sponsor

Lead sponsor
Outpace Bio, Inc.Industry
Sponsor type
Industry
First posted
Jun 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.

Conditions

  • Endometrial Cancer Recurrent
  • Endometrial Cancer
  • Advanced Endometrial Cancer
  • Ovarian Cancer
  • Ovarian Cancer Recurrent
  • Platinum Resistant Ovarian Cancer
  • Endometrial Cancers

Interventions

  • OPB-201Biological

    A multi-transgene autologous TCR T cell therapy with optimized alpha and beta chains of a TCR specific for a peptide derived from PRAME and a designed protein which enhances TCR T cell potency.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of all treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs); deaths due to TEAEs and all deaths.Time frame: 2 years
  2. Incidence of dose-limiting-toxicities (DLTs)Time frame: 28 days
  3. To determine the maximum tolerated dose (MTD) of OPB-201 and/or recommended Phase 1b dose(s)Time frame: 2 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • UCSF - Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Emory - Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.